Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies by Diaz Miqueli, A et al.
Radiosensitisation of U87MG brain tumours by anti-epidermal
growth factor receptor monoclonal antibodies
A Diaz Miqueli*,1, J Rolff
2, M Lemm
2, I Fichtner
2, R Perez
1 and E Montero
1
1Department of Experimental Immunotherapy, Centre of Molecular Immunology, P.O. Box 16040, 214 Street, Havana 11600, Cuba;
2Department of
Experimental Pharmacology, Max Delbru ¨ck Center for Molecular Medicine. Robert-Ro ¨ssle-Strasse 10, Berlin-Buch 13125, Germany
As epidermal growth factor receptor (EGFR) has been reported to be a radiation response modulator, HER inhibitors are regarded
to act as potential radiosensitisers. Our study examined the role of nimotuzumab and cetuximab both, the two monoclonal
antibodies (mAbs) to EGFR, as radiosensitisers in a murine glioma model in vivo. Co-administration of both the antibodies with
radiation increased the radiosensitivity of U87MG, resulting in a significant delay of subcutaneous (s.c.) tumour growth. Furthermore,
the addition of antibodies to the radiation decreased brain tumour sizes and is inhibited by 40–80% the increased tumour cell
invasion provoked by radiotherapy, although promoted tumour cell apoptosis. Whereas nimotuzumab led to a reduction in the size
of tumour blood vessels and proliferating cells in s.c. tumours, cetuximab had no significant antiangiogenic nor antiproliferative activity.
In contrast, cetuximab induced a more marked inhibition of EGFR downstream signalling compared with nimotuzumab. Moreover,
both antibodies reduced the total number of radioresistant CD133þ cancer stem cells (CSCs). These results were encouraging, and
showed the superiority of combined treatment of mAbs to EGFR and radiation over each single therapy against glioblastoma
multiforme (GBM), confirming the role of these drugs as radiosensitisers in human GBM. In addition, we first showed the ability of
mAb specifics against EGFR to target radioresistant glioma CSC, supporting the potential use in patients.
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Glioblastoma multiforme (GBM) remains a deadly disease with
a median survival of o1 year despite all therapeutic efforts based
on the aggressive conventional anticancer therapies (Quigley et al,
2007). An attempt to improve local control of the disease and
overall survival of patients with GBM has considered the possi-
bility to add newer forms of treatment with conventional therapies
such as chemo- and radiotherapy (Hauch et al, 2005).
A well-known validated target for molecular anticancer-targeted
therapies is the epidermal growth factor receptor (EGFR) (Prenzel
et al, 2001). There is strong evidence in support of this: EGFR is
frequently overexpressed in B40% of GBMs, its overexpression
correlates with a poor prognosis in patients, and early studies
using specific anti-EGFR agents have shown efficacy to increase
survival in mice xenotransplanted with tumours directly estab-
lished from patients (Eller et al, 2002). Indeed, several of these
agents have entered its evaluation in patients given alone or in
combination with conventional therapies (e.g. radiotherapy). In
addition, such studies have correlated the overexpression of the
EGFR with radioresistance (Barker et al, 2001; Bonner et al, 2004),
whereas the EGFR blockade increases the sensitivity of tumour
cells to radiation therapy (Huang and Harari, 2000).
Among EGFR inhibitors, nimotuzumab (TheraCIM h-R3) and
cetuximab (IMC-C225) have undergone an extensive evaluation in
different tumour locations, showing activity when administered
with ionising radiation (Bonner et al, 2004; Crombet et al, 2004;
Ramos et al, 2006). However, these studies did not dissect
comparatively the contribution of individual therapies for such
antitumour effect. To investigate the advantages resulting from the
addition of anti-EGFR antibodies to the radiation therapy over a
single-agent therapy, we investigated the growth-inhibitory effects
of both nimotuzumab and cetuximab, alone and in combination
with radiation in a human GBM xenografted in NMRI nude mice.
We also explored potential mechanisms of such antitumour
activity underlying the therapeutic effect.
MATERIALS AND METHODS
Cell culture
U87MG (ATCC HTB-14, Rockville, MD, USA) is a human GBM
cell line. Cells were grown in a 1þ1 mixture of Eagle’s minimum
essential medium and Basal medium, (Sigma, St Louis, MO,
USA) containing 2mML -glutamine and 10% foetal bovine
serum, and were maintained under a humidified atmosphere of
5% CO2 at 371C.
Antibodies
The human–mouse chimeric anti-EGFR monoclonal antibody
(mAb) cetuximab was provided by ImClone Systems, Inc. (New
York, NY, USA). The humanised anti-EGFR mAb nimotuzumab
was generated at the Centre of Molecular Immunology (Mateo
et al, 1997). All the primary and secondary antibodies were Revised 15 January 2009; accepted 22 January 2009
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spurchased from commercial sources listed as follows: rabbit
polyclonal EGFR antibody to total EGFR (Santa Cruz Biotechno-
logy Inc., Santa Cruz, CA, USA), mouse monoclonal anti-phospho-
tyrosine antibody (BD Pharmingen, San Diego, CA, USA), mouse
monoclonal ERK1/2 antibody to total ERK1/2 (BD Pharmingen),
rabbit polyclonal phospho-p44/42 MAPK (Thr202/Tyr204) anti-
body to activated ERK1/2 (BD Pharmingen), mouse monoclonal
antibody MIB-1 to Ki-67 (DakoCytomation, Carpinteria, CA, USA),
rat monoclonal anti CD31/PECAM-1 antibody (BD Pharmingen),
biotin-conjugated mouse monoclonal antibody to CD133/1
(AC133) (Miltenyi Biotec, Cologne, Germany). The secondary
antibodies used were as follows: horseradish peroxidase (HRP)-
conjugated anti-rat IgG1 (Southern Biotech, Birmingham, AL,
USA), HRP-conjugated anti-rabbit IgG (DakoCytomation) and
HRP-conjugated anti-mouse IgG (DakoCytomation).
Proliferation index (Ki-67), angiogenesis (CD31/PECAM-1),
apoptosis (TUNEL) and immunohistochemistry
Until analysis all the specimens were shock frozen and stored in
nitrogen. Immunostaining was performed using 5-mm tissue
sections placed on glass slides. The proliferation index was
calculated from tissue sections stained using an indirect immuno-
peroxidase technique that employed the biotinylated clone MIB-1
(1:50 dilution) as primary antibody, which is specific for the Ki-67
protein, a marker of proliferating cells, followed by incubation
with streptavidine/HRP (DakoCytomation). At least 5 high-power
fields were counted and scored per sample. To score a tumour cell
as positive for Ki-67, a nuclear staining was required. For this
methodology, tumour slices were fixed with Fix I solution (NKH
(8gl
 1 NaCl and 0.4gl
 1 KC1 buffered with 0.1 M Hepes, pH 7.4),
1 M HEPES, 25% glutaraldehyde, 1% glucose). All other immuno-
histochemical stains were performed on paraformaldehyde-fixed,
cryostat 5-mm tissue sections using standard techniques. The
following primary antibodies were used: anti-human CD133/1
(1:10 dilution), anti-human EGFR (1:500 dilution) and anti CD31/
PECAM-1 (1:100 dilution). After washing, corresponding HRP-
conjugated secondary antibody were used to detect antibody–
antigen reactions. The negative controls consisted of duplicate
sections of the same specimens, in which the primary antibody had
been excluded and replaced with PBS or negative control
immunoglobulin. The sections were visualised with 3,30-diamino-
benzidine as a chromogen and counterstained with Mayer’s
hematoxylin. Representative tumour sections were identified on
a light microscope (Zeiss, Axioskop 40) with an ocular magnifica-
tion of  40 evaluating 4–5 tumours from each group for the
corresponding analysis. To score a tumour cell as positive, a
complete membrane staining was required for EGFR and CD133.
Total area of the endothelial blood microvessels was calculated
using the software (Axio Vison 4.5). Fluorescent terminal-deoxy-
nucleotidyl-transferase-mediated nick end labelling (TUNEL) to
evaluate apoptosis was done as per the manufacturer’s instructions
(Roche Diagnostics, Mannheim, Germany). Slides were analysed in
a drop of PBS with a fluorescence microscope (Zeiss, Axioskop 40)
in five random fields at  40 magnification.
Western blotting
Western blotting experiments were performed as described (Diaz
et al, 2007). Briefly, tumour lysates were fractioned by sodium
dodecyl sulphate–polyacrylamide gel electrophoresis on a 7.5%
gel, and the separated proteins were transferred to a nitrocellulose
membrane. After blocking of non-specific sites, the membrane was
incubated with primary antibodies to activated EGFR (1:500
dilution), total ERK1/2 (1:500 dilution), activated ERK1/2 (1:1000
dilution) and total EGFR (1:500 dilution). Subsequently, mem-
branes were incubated with the corresponding HRP-conjugated
secondary antibody. Bound antibody was visualised using a
western blotting chemiluminescence luminol reagent system
(Santa Cruz Biotechnology).
Animal experiments
Female athymic mice (8–10 weeks old, nu/nu) were obtained from
Charles River (Sulzfeld, Germany). The mice were housed and
maintained under aseptic conditions in facilities approved by the
German Association for Accreditation of Laboratory Animal Care
and in accordance with current regulations and standards of the
German Animal Protection Law, and their use was approved by
the local responsible authorities. Animals met the requirements of
the UKCCCR guidelines (1998). To produce xenografts, tumour
cells were harvested from subconfluent cultures by treatment with
0.25% trypsin and 0.05% EDTA. Only single-cell suspensions with
490% viability were used for injections. Animals were inoculated
with both 10
7 U87MG tumour cells subcutaneous (s.c.) into left
flank and 2 10
4 cells intracranially into the right hemisphere of
mouse brains with the help of a stereotactic device. Tumour
volume from flank’s were determined from direct measurement
with callipers and calculated according to the formula as follows:
0.5 (large diameter) (small diameter)
2. Relative tumour
volumes (RTV) were calculated by referring the median volumes
of each day to the first measurement (set to 1) as described
(Mansour et al, 2003). Treatments were initiated 3 days after
tumour cell injection. Treatment groups consisted of control,
nimotuzumab or cetuximab alone, radiation alone, and the
combination of each antibody and radiation, with each group
containing eight mice, except the control group containing ten
mice. Both antibodies were administered intraperitoneal three
times per week with 1mg per mouse, (50mgkg
 1) mice in the
control and radiation-alone groups were injected with saline
solution. For radiation groups, animals were exposed to a total
dose of 3.0Gy of total body radiation fractioned in 1.0Gy weekly.
In the combination group the antibodies were administered 6h
before radiation therapy. All animals were killed by day 28 when
tumour weight from the control group exceeded the 10% of total
animal weight. These studies were repeated twice both for
subcutaneous and intracranial tumours.
The size of intracranial tumours was determined. For that
purpose, brains were collected and shock frozen in 2-methyl-
butane. Sequential cryosections (10mm) were prepared and stained
with cresyl violet. At the area of largest dimensions tumour
diameters and perimeters were determined by computer-assisted
image with the help of a microscope (Zeiss Axioskop 40).
Subcutaneous tumours were snapping frozen and stored at
 801C for additional analyses.
Statistical analysis
Statistical analysis was performed using the GraphPAD Prism
software for Windows, version 4.0 (GraphPAD, San Diego, CA,
USA). The significance of differences between groups was
compared using a Kruskal–Wallis test. The significance of
differences in groups was compared using Dunn0s multiple
comparison test. Differences were considered significant if
Po0.05.
RESULTS
Radiosensitisation of U87MG tumours xenografted
subcutaneously in vivo with anti-EGFR mAb
Human U87MG GBM cell line sensitivity to radiation is influenced
by the experimental conditions (Suit et al, 1990; Eshleman et al,
2002), allowing to evidence combinatorial effects when used
concomitantly to other therapeutic approaches (Wachsberger et al,
2007).
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sHere, we explored the combinatorial effect of the EGFR targeted
therapy based on mAbs with radiotherapy. U87MG cell line was
xenografted both in the flanks and in the brains of NMRI nude
mice. All animals injected with the tumour cells developed
tumours. The mice were then treated with either nimotuzumab
or cetuximab, radiation or both modalities during 3 weeks.
Figure 1 shows the RTV of treated groups at different time points.
Combined treatment with radiation and antibodies resulted in a
substantial growth delay and subsequent inhibition of the growth
rate of U87MG xenografts with a maximum effect by day 28, that
is: media RTV for h-R3þRT (2.2) and C255þRT (2.8) vs control
(3.5). In contrast, radiation and antibodies each as a single
modality treatment did not affect tumour growth profiles
compared with controls. Further, no significant decreases in body
weight were observed in mice in any of the six treatment groups.
These results suggest that nimotuzumab and cetuximab may
enhance the antitumour activity of radiation in U87MG tumours
in vivo.
Inhibition of tumour invasion promoted by radiation in
U87MG tumours in vivo by anti-EGFR mAb
To reproduce a closer real life situation, we examined whether
these antibodies may enhance the antitumour activity of radiation
in U87MG tumours implanted in the brain of athymic mice. In the
orthotopic model (Figure 2A), the radiation failed to show a
statistical reduction in brain tumour size (P40.05), as well as each
antibody given alone. In contrast, only the combination of each
antibody with radiation reduced significantly (Po0.05) the growth
of orthotopic tumours; for example: tumour perimeter (mean±
s.e.m.) for h-R3þRT (5.2±0.9) and C255þRT (5.4±1.2) versus
control (11.1±2.1). More interesting, a histopathological analysis
of intracranial tumour sections showed a strikingly more invasive
growth pattern in mice treated with radiotherapy alone compared
with antibodies-based therapies. These tumours were usually
surrounded by numerous small-satellite tumours (Figure 2B).
Quantification of these satellites showed that the satellite frequency
(median, min–max) was increased over 40% in mice exposed to
radiotherapy (26, 11–51) compared with control (18, 3–40).
Contrastingly, in mice receiving antibodies-based therapies a
40–80% of reduction in the number of satellite tumours was
documented; that is: h-R3þRT (9, 1–25) and C255þRT
(4, 0–17). Interestingly, monotherapy with both antibodies also
display a reduction in the frequency of satellite tumour; that is:
h-R3 (10, 0–24) and C255 (10, 0–26) (Supplementary Table 1).
These results suggest that both antibodies may increase the radio-
sensitisation of U87MG tumours in the brain of mice, whereas
decrease the satellite tumour formation induced by radiation.
Radiosensitisation of U87MG tumours by anti-EGFR mAb
in vivo occurred by different mechanisms
To evaluate mechanisms underlying the antitumour effect
described above, an immunohistochemical analysis was done at
the end of the treatment in tumour specimens excised from the s.c.
area. A positive EGFR immunostaining was detected in all analysed
tumour samples (Figure 3). Furthermore, data scored from þ1
to þ4 as per immunostaining intensity was blinded evaluated
resulting nearly identical in each treatment group, indicating no
differences in the EGFR expression level in analysed tumours (Data
not shown). EGFR expression was also verified by western blot
analysis, showing similar results (Supplementary Figure 1).
Given that angiogenesis is considered a process of neovascular-
isation particularly pertinent in gliomas that permits malignant
cells spread diffusely as the brain is a highly vascularised organ, we
evaluated whether both antibodies might inhibits angiogenic
processes in this glioma model. A quantitative analysis of the
blood vessels stained with the specific endothelial marker CD31
did not show differences in the microvessel density of s.c. tumours
(Figure 4A), but showed striking differences in the size of the
vascular channels (expressed as median in mm±s.e.m.), among
different group of treatments (Figures 3 and 4B). Whereas tumours
in mice treated with nimotuzumab, exhibited a significant reduc-
tion (two-folds) in the vessel size (113.4±8.2), many enlarged
vessels were found in control mice (333.3±31.6) or treated with
radiation alone (228.3±18.6). These mice exhibited highly
enlarged vessels forming complex structures suggestive of splitting
of the vessel lumen by endothelial intravessel walls (Figure 3).
Furthermore, similar reductions in the size of blood vessels after
treatment with nimotuzumab alone, or both nimotuzumab and
radiation (135.8±10.1), suggested that the antiangiogenic activity
was mainly associated to the use of the antibody. These results
indicate that no higher antiangiogenic potential between radiation
and the antibody for the doses chosen could be expected; despite
the antitumour activity observed with both therapies seems to be
higher than expected by independent treatments. In contrast, in
mice treated with cetuximab, similar reductions in the size of
the vessels were observed only when the antibody was added to
the radiotherapy (188.3±16.5), but it was mainly attributable to
the effect of the radiation, indicating no significant antiangiogenic
activity for cetuximab.
Antiangiogenic and pro-apoptotic processes are commonly
linked to the activity of the anti-EGFR agents. Subsequently,
spontaneous apoptosis (TUNEL) in the control group was negli-
gible, sharply contrasting with the different groups of treatment;
however, no statistical differences between them were found
(Figure 3).
We next examined whether both antibodies might enhance the
antiproliferative effect of radiation by analysing the Ki-67
expression. The analysis of the proliferative activity in these
tumours showed that, nimotuzumab enhanced the inhibition of
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Figure 1 Sensitization of U87MG human tumour subcutaneously
xenografted into NMRI nude mice to radiation by anti-EGFR mAb. Cells
were injected subcutaneously in athymic mice. Treatments were initiated 3
days after tumour inoculation with J nimotuzumab (h-R3), or n
cetuximab (C225), 50mgkg
 1 intraperitoneally, three times per week by
3 weeks, or ’ radiation (RT), 3Gy fractioned in 1Gy weekly, or both
modalities K (h-R3þRT), m (C225þRT) or & PBS control (PBS).
Antibody administrations are showed as black arrows and radiation as
fractioned arrows. Tumour volume was determined at the indicated time
thereafter and RTV were calculated. Error bars are not shown because of
better clarity. Kruskal–Wallis test; symbols indicate statistical differences as
follows: *Significant to PBS, þsignificant to antibody alone, 1significant to
radiation.
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sproliferation caused by radiation by 56.5% in the combination
group, compared with the antibody alone or radiotherapy (39.9 or
19.9%, respectively; Figures 3 and 4C). These results indicate an
antiproliferative effect of nimotuzumab alone that may by further
augmented when combined to radiation. Cetuximab in contrast,
did not produce a significant inhibition on cell proliferation
neither alone (7.8%), nor added to radiotherapy (21.7%). More-
over, a statistical reduction (Po0.05) on cell proliferation was
reached between the two groups of combination.
Enhanced inhibition of EGFR signalling in U87MG
tumours by anti-EGFR mAb in vivo
To further examine potential advantages of the combined therapy
over a single-drug treatment, we determined the effect of different
treatments on EGFR signalling by western blotting. Constitutive
activation of EGFR was unaffected in mice treated with nimo-
tuzumab, although it increased after radiation alone (Figure 5,
upper panel). In contrast, a more pronounced decrease in the
phosphorylation of ERK1/2 proteins was observed after treatment
with nimotuzumab and radiation, compared with each single
therapy (Figure 5, middle panel), indicating that the inhibition of
EGFR signalling by nimotuzumab may increase by using the
antibody in addition to radiation, consistent with the inhibitory-
growth effects of combined therapies, whereas the same effect was
not corroborated with radiation alone. On the other hand, tumours
in mice treated with cetuximab exhibited a complete abrogation in
the levels of phosphorylation of EGFR and ERK even when the
antibody was administered as a single agent. These results indicate
a higher capacity to block EGFR signalling in tumour cells for
cetuximab, compared with nimotuzumab, accordingly with earlier
findings (Diaz Miqueli et al, 2007). Moreover, the different
PBS
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Figure 2 Sensitization of U87MG human tumour orthotopically xenografted into NMRI nude mice to radiation by the anti-EGFR mAb. (A) Cells were
injected intracranially in athymic mice. Treatments were initiated 3 days after tumour inoculation. The antibody was administered at 50mgkg
 1
intraperitoneally, three times per weeks by 3 weeks. Animals receiving radiation were exposed to a total dose of 3Gy fractioned in 1Gy weekly. (B) Stained
sections show the extent and morphology of tumours treated with PBS control (PBS), radiation alone (RT), nimotuzumab alone (h-R3), or cetuximab alone
(C225), or both modalities. Analysed brain sections from mice showed a remarkable reduction in the number of small satellite tumours in the groups of mice
treated with the antibodies alone or in combination with radiation. Kruskal–Wallis test; symbols indicate statistical differences as follows: *Significant to PBS,
1significant to radiation.
Anti-EGFR mAb enhance radiosensitivity of glioma tumour
A Diaz Miqueli et al
953
British Journal of Cancer (2009) 100(6), 950–958 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
streatments did not produce significant changes in the endogenous
levels of ERK proteins (Figure 5, bottom panel).
Targeting of CD133þ radioresistant cancer stem cell in
U87MG tumours in vivo by anti-EGFR mAb
Brain tumour growth has recently postulated being critically
dependent on the presence of an intact cancer stem cell (CSC)
vascular niche, representing a potential target for treatments of
brain tumours (Calabrese et al, 2007). We therefore investigated
whether anti-EGFR mAb might reduce the number of CSC from
this brain tumour. As glioma subpopulations expressing Promi-
nin-1 (CD133þ) are enriched for CSC, which mark quite speci-
fically brain CSC, we quantified the expression of CD133þ cells in
U87MG tumours. As shown in Figures 6A and B, co-administration
of both antibodies with radiation was associated to a significant
reduction in the total number of CD133þ cells in analysed
tumours specimens. The frequency of CD133þ cells per field
(mean±s.e.m.) decreased from 4.7±0.8 in control mice to 0.8±
0.4 and 1.7±0.4 in mice receiving h-R3þRT and C225þRT,
respectively. Coincidently to the effect observed on satellite
tumours, animals treated with h-R3 or C225 mAb as mono-
therapies, displayed a significant reduction in the frequency of
CD133þ cells per field (2.7±0.6 and 2.3±0.4, respectively),
compared with radiotherapy (5.4±0.6).
Radiation alone resulted in slightly non-significant increases
in the percentages of CD133þ cells relative to untreated mice, in
line with earlier reports obtained in cultures from human glioma
EGFR
PBS
h-R3
RT
h-R3+RT
C225
C225+RT
Ki-67 TUNEL CD31
Figure 3 Tissue-based studies of U87MG human tumours xenografted into NMRI nude mice treated with nimotuzumab (h-R3), or cetuximab (C225), or
radiation alone (RT), or both modalities. Immunohistochemical analysis of tumour cells stained with anti-EGFR, anti-Ki-67 nuclear antigen, apoptosis by
TUNEL and angiogenesis with anti-CD31 antibody ( 40 magnification).
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sxenografts (Bao et al, 2006). These results may suggest that anti-
EGFR mABs may radiosensitisate U87MG brain tumours.
DISCUSSION
Despite aggressive therapies, malignant gliomas remains resistant
to all currently used conventional treatment modalities, such as
radiation and chemotherapy. Current research focuses on im-
munotherapy as a novel approach of targeted molecular therapies
on glioma treatment, on the basis of the presence of potential
antigens such as EGFR (Barker et al, 2001). Radiosensitisation of
tumour cell mediated by EGFR antagonists is supported by
preclinical and clinical studies (Bonner et al, 2006; Ramos et al,
2006), also suggesting the possibility of successful radiosensitisa-
tion in this setting. To better understand the influence of the EGFR
blockade on radiation response in GBM, we investigated the
antitumour effect of combined treatment with two mAb to EGFR
and radiation in human tumour U87MG xenografts.
The antitumour effect of anti-EGFR mAbs in combination with
radiotherapy has been thought to result from the enhancement of
the inhibition of EGFR signalling, increasing the cytotoxic effect of
the radiation (Akashi et al, 2008). Consistent with these results, we
found that treatment with nimotuzumab and radiation enhanced
the inhibition of EGFR-signalling activation, supporting a notion
that the inhibition of ERK-mediated signalling is related to
radiation response in vivo in GBM (Xia et al, 1995). Such
inhibition was not apparent for tumours treated with radiation
alone, suggesting a rationale for combined treatment with anti-
EGFR mAbs and radiotherapy. Contrastingly, no antitumor
activity was observed in mice treated with cetuximab alone,
despite inhibiting completely EGFR signalling, suggesting that
different mechanisms of action of the two antibodies underwent
the enhancement of the cytotoxic effects of radiation. Whereas
cetuximab seems to affect the tumour cells directly, by abrogating
EGFR activation, nimotuzumab would target both endothelial cells
and tumour cells through a significant anti-angiogenic activity.
Nimotuzumab was shown earlier to induce the regression of A431
tumour xenografts in vivo as a result of a potent antiangiogenic
activity. One of the endothelial-specific growth factors often
associated with tumour angiogenesis is vascular endothelial
growth factor (VEGF) (Johnson et al, 2007). Further, a close
relationship between EGFR/VEGF has been postulated to promote
angiogenesis (Rak et al, 2000). Whereas earlier studies indicated
that VEGF is induced in tumours after irradiation (Gorski et al,
1999), nimotuzumab has shown to downregulate VEGF expression
at the RNA and protein level after treatment in A431 tumour
xenografts in vivo (Crombet-Ramos et al, 2002). In agreement with
that, we found a 60% of reduction in the total area of the vessels in
tumour specimens from mice treated with nimotuzumab. Whether
a two-fold reduction in the area of the vessels would translate into
a significant antitumour activity remains unclear, suppression of
VEGF expression in a GBM cell line, in the order of three-fold, has
reported to abrogate its growth in nude mice (Cheng et al, 1996).
In line with these considerations, the targeting of the vascular
microenvironment in brain tumours to arrest tumour growth has
been proposed to explain mechanisms associated to drugs with
antiangiogenic potential (Calabrese et al, 2007). These observa-
tions suggest that an antiangiogenic and targeted therapy against
both endothelial cells and tumour cells may inhibit brain tumour
growth by disrupting the vascular endothelial microenvironment,
in addition to abrogate the EGFR activation.
Interestingly, CSC has been identified as a new cellular subpopu-
lation of brain tumour cells with potent tumourigenic activity
(Hemmati et al, 2003; Singh et al, 2003). As glioma subpopulations
CD133þ show greater tumourigenic potential than do CD133 
cells, an important role in the development of glioma radio-
resistance has been conferred to these cells (Bao et al, 2006).
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Figure 4 Comparisons between tumours treated with PBS control
(PBS), or nimotuzumab (h-R3), or cetuximab (C225), or radiation alone
(RT), or both modalities. (A, B) Angiogenesis by vessel density and vessel
area. (C) Proliferation index by Ki-67. Kruskal–Wallis test; symbols indicate
statistical differences as follows: *Significant to PBS (Po0.001),
Nsignificant
to cetuximab alone (Po0.001), 1significant to radiation (Po0.01),
asignificant to cetuximab plus radiation (Po0.05).
pEGFR 170 kDa
12 3 4 5 6
pERK 1/2
(p44/42)
ERK 1/2
(p44/42)
Figure 5 EGFR and ERK1/2 phosphorylation in U87MG tumours
xenografted into NMRI nude mice after treatment with nimotuzumab, or
cetuximab, or radiation alone, or both modalities. Immunoblot analysis of
(upper panel) tyrosine phosphorylated EGFR, or (middle panel) activated
ERK1/2, or (bottom panel) ERK1/2 protein expression in tumours. Lane 1
PBS control, lane 2 nimotuzumab, lane 3 radiation, lane 4 nimotuzumab
plus radiation, lane 5 cetuximab, lane 6 cetuximab plus radiation.
Immunoblots were developed using chemiluminescence. Abbreviations:
pEGFR, receptor tyrosine phosphorylation; ERK1/2, Extracellular signal-
regulated kinases 1 and 2. Pictures show one representative example per
group out of four samples analysed.
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endothelial cells and these brain CSCs resulting in the initiation
and growth of tumours (Calabrese et al, 2007). Therefore, ongoing
investigation has linked the therapeutic activity of antiangiogenic
therapies against GBM to their intrinsic capacity to deplete tumour
blood vessels and CSC. These findings might support the use of
tumour microvasculature targeted therapies in the design of future
therapeutic approaches against brain tumours. Despite future
investigations are needed to elucidate the role of anti-EGFR agents
on specific CD133þ CSC, this study has first suggested the
feasibility of targeting this radioresistant cell subpopulation by
using specific anti-EGFR mAbs against GBM.
A question emerging from this study was the lack of therapeutic
response when nimotuzumab was given alone, despite shown a
significant antiangiogenic activity. The reason is not fully under-
stood, but it is likely that a combination of different mechanisms is
needed to translate into a relevant therapeutic response. Indeed,
the combined treatment with nimotuzumab and radiotherapy
enhanced the antiproliferative activity of both drugs compared
with individual therapies. Similarly, the absence of activity of
cetuximab given alone, despite the abrogation of the EGFR
signalling, suggest that it is at least in part responsible for the
enhancement of the cytotoxic effects of radiation, but not enough
to produce a substantial therapeutic response.
More important, both antibodies displayed capacity to inhibit
the tumour cell invasion provoked by the radiotherapy. It has
established that the blockade of angiogenesis leads to compensa-
tory mechanisms by which tumours may recruit their own vascular
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Figure 6 Tissue-based studies of U87MG human tumours xenografted into NMRI nude mice treated with nimotuzumab (h-R3), or cetuximab (C225), or
radiation alone (RT), or both modalities, or neither (PBS). (A) Cryostat sections were fixed and immunostained with CD133/1 (AC133) antibody yielding a
staining pattern typical for membrane ( 40 magnification). (B) Comparisons between groups. Kruskal–Wallis test; symbols indicate statistical differences
(Po0.05) as follows: *Significant to PBS, 1significant to radiation.
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ssupply from pre-existent vessels and grow despite the absence of
neovascularisation, a phenomenon named as vessel co-option
(Holash et al, 1999). Furthermore, EGFR signalling can strongly
stimulate GBM cell migration and invasion (Lund-Johansen et al,
1990). In line with these findings, Cetuximab has shown to inhibit
the increased glioma cell invasion after the therapy with DC101, a
mAb against VEGFR-2 with a potent antiangiogenic activity
(Lamszus et al, 2005). In sum, these data point out that the
success of either ionising radiation or antiangiogenic therapies
may increase by simultaneous blockade of EGFR.
Glioma invasiveness has been linked to the development of
local tumour satellites modulated after therapeutic interventions
(Lamszus et al, 2005). That observation was corroborated in our
experimental conditions (Figure 2B and Supplementary Table 1).
A current paradigm postulates that irradiation in a dose-
dependent manner promotes migration and invasiveness of glioma
cells (Wild-Bode et al, 2001). This effect involves remodelling and
the growth of experimental tumours (Brooks et al, 1996; Silletti
et al, 2001; Wild-Bode et al, 2001; Wick et al, 2002). The recent
demonstration that irradiation increases circulating levels of
TGF-b, circulating cancer cells and tumour metastases by a direct
effect of the TGF-b on the cancer cells may also contribute
to explain that unexpected biological effect of radiotherapy
(Biswas et al, 2007).
Furthermore, the possible interrelations of TGF-b, proteins of
the BCL-2 family, integrins and metalloprotease activity may
promote glioma invasion (Wick et al, 2001). Others have suggested
that TGF-b could mediate EGFR transactivation, and subsequently
activate ERK and p38MAPK through PKC (Uchiyama-Tanaka
et al, 2002).
In addition, radiation therapy may enhance the EGFR intra-
cellular activation pathways after irradiation, which in turn may
contribute to enhance the tumour invasiveness (Figure 5). EGFR in
the context of the human gliomas results in a strong stimulator of
tumour cell migration and invasion (Lund-Johansen et al, 1990;
Penar et al, 1997; Lamszus et al, 2005). Despite more investigation
is needed, these evidences suggest that the blockade of the EGFR
by specific mAbs may antagonise the role of the TGF-b on promote
tumour cell invasion and metastasis after a radiation therapy.
In summary, we have provided evidence that nimotuzumab and
cetuximab, two specifics mAb to EGFR, may increase the radio-
sensitivity of human U87MG tumour, enhancing the antitumour
efficacy of radiation in vivo. This work may enhance our
preclinical understanding of the interaction of radiation and the
inhibition of the EGFR to increase radiation-induced tumour
toxicity. This information further serves as preclinical background
for clinical investigations involving anti-EGFR antibodies with
radiation in human GBM, a tumour relatively resistant to the
treatment with other well known anti-EGFR agents, such as Iressa
and Tarceva (Newton, 2003; Rich et al, 2004).
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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